481 | Humans (MeSH) |
323 | Netherlands (epidemiology) |
258 | Netherlands (MeSH) |
228 | Female (MeSH) |
218 | Male (MeSH) |
201 | Influenza, Human (epidemiology) |
166 | Middle Aged (MeSH) |
164 | Influenza, Human (prevention & control) |
163 | Animals (MeSH) |
159 | Adult (MeSH) |
152 | Aged (MeSH) |
103 | Adolescent (MeSH) |
91 | Influenza in Birds (epidemiology) |
85 | Child, Preschool (MeSH) |
84 | Child (MeSH) |
81 | Infant (MeSH) |
77 | Influenza Vaccines (administration & dosage) |
74 | Influenza, Human (virology) |
66 | Aged, 80 and over (MeSH) |
60 | Seasons (MeSH) |
60 | Influenza in Birds (virology) |
59 | Young Adult (MeSH) |
56 | Disease Outbreaks (MeSH) |
55 | Surveys and Questionnaires (MeSH) |
53 | Incidence (MeSH) |
52 | Disease Outbreaks (veterinary) |
51 | Influenza A virus (isolation & purification) |
50 | Risk Factors (MeSH) |
48 | Influenza in Birds (transmission) |
46 | Poultry (MeSH) |
42 | Infant, Newborn (MeSH) |
41 | Influenza, Human (mortality) |
40 | Vaccination (statistics & numerical data) |
39 | Disease Outbreaks (prevention & control) |
34 | Retrospective Studies (MeSH) |
34 | Influenza Vaccines (immunology) |
34 | Influenza Vaccines (MeSH) |
31 | Influenza A virus (pathogenicity) |
31 | Influenza A virus (immunology) |
30 | Influenza in Birds (prevention & control) |
29 | Influenza A Virus, H1N1 Subtype (MeSH) |
28 | Influenza, Human (immunology) |
28 | Influenza Vaccines (therapeutic use) |
27 | Influenza, Human (transmission) |
27 | Influenza, Human (drug therapy) |
26 | Poultry Diseases (epidemiology) |
26 | Population Surveillance (MeSH) |
26 | Influenza, Human (diagnosis) |
26 | Birds (MeSH) |
26 | Antiviral Agents (therapeutic use) |
25 | Chickens (MeSH) |
25 | Age Factors (MeSH) |
24 | Vaccination (MeSH) |
24 | Influenza Vaccines (adverse effects) |
24 | Antibodies, Viral (blood) |
23 | Sentinel Surveillance (MeSH) |
23 | Respiratory Tract Infections (epidemiology) |
23 | Prospective Studies (MeSH) |
23 | Influenza, Human (complications) |
23 | Cross-Sectional Studies (MeSH) |
23 | Cost-Benefit Analysis (MeSH) |
22 | Cohort Studies (MeSH) |
21 | Prevalence (MeSH) |
21 | Influenza A virus (classification) |
21 | Influenza A Virus, H1N1 Subtype (immunology) |
20 | Time Factors (MeSH) |
20 | Influenza A virus (genetics) |
20 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
19 | Swine (MeSH) |
19 | Health Knowledge, Attitudes, Practice (MeSH) |
18 | Poultry Diseases (virology) |
18 | Hospitalization (statistics & numerical data) |
18 | Hemagglutination Inhibition Tests (MeSH) |
16 | Risk Assessment (MeSH) |
16 | Orthomyxoviridae (isolation & purification) |
16 | Odds Ratio (MeSH) |
16 | Influenza B virus (isolation & purification) |
15 | Pregnancy (MeSH) |
15 | Population Surveillance (methods) |
15 | Pandemics (MeSH) |
15 | Influenza B virus (immunology) |
15 | Influenza A virus (MeSH) |
15 | Attitude of Health Personnel (MeSH) |
14 | Orthomyxoviridae Infections (virology) |
14 | Internet (MeSH) |
13 | Treatment Outcome (MeSH) |
13 | Sensitivity and Specificity (MeSH) |
13 | Regression Analysis (MeSH) |
13 | Practice Guidelines as Topic (MeSH) |
13 | Phylogeny (MeSH) |
13 | Pandemics (prevention & control) |
13 | Oseltamivir (therapeutic use) |
13 | Mortality (MeSH) |
13 | Models, Biological (MeSH) |
13 | Influenza A Virus, H7N7 Subtype (MeSH) |
13 | Disease Outbreaks (statistics & numerical data) |
13 | Cause of Death (MeSH) |
13 | Age Distribution (MeSH) |
12 | Risk (MeSH) |
12 | Respiratory Tract Infections (virology) |
12 | Public Health (MeSH) |
12 | Nursing Homes (MeSH) |
12 | Influenza, Human (economics) |
12 | Influenza in Birds (diagnosis) |
12 | Health Personnel (MeSH) |
12 | Family Practice (MeSH) |
12 | Case-Control Studies (MeSH) |
12 | Animal Husbandry (MeSH) |
11 | Vaccination (psychology) |
11 | Vaccination (economics) |
11 | United States (MeSH) |
11 | United Kingdom (epidemiology) |
11 | Seroepidemiologic Studies (MeSH) |
11 | Orthomyxoviridae Infections (epidemiology) |
11 | Models, Theoretical (MeSH) |
11 | Models, Statistical (MeSH) |
11 | Logistic Models (MeSH) |
11 | Influenza in Birds (pathology) |
11 | Immunization Programs (MeSH) |
11 | Chickens (virology) |
11 | Animal Migration (MeSH) |
10 | Zoonoses (MeSH) |
10 | Sex Distribution (MeSH) |
10 | Influenza, Human (psychology) |
10 | Influenza, Human (microbiology) |
10 | Influenza in Birds (mortality) |
10 | Influenza Vaccines (economics) |
10 | Germany (epidemiology) |
10 | Cost of Illness (MeSH) |
10 | Birds (virology) |
9 | Severity of Illness Index (MeSH) |
9 | Sequence Analysis, DNA (MeSH) |
9 | Respiratory Tract Infections (diagnosis) |
9 | Registries (MeSH) |
9 | RNA, Viral (genetics) |
9 | Poultry Diseases (prevention & control) |
9 | Orthomyxoviridae Infections (veterinary) |
9 | Orthomyxoviridae Infections (transmission) |
9 | Longitudinal Studies (MeSH) |
9 | Influenza A Virus, H7N7 Subtype (pathogenicity) |
9 | Influenza A Virus, H5N1 Subtype (pathogenicity) |
9 | Influenza A Virus, H5N1 Subtype (MeSH) |
9 | Influenza A Virus, H1N1 Subtype (genetics) |
9 | Health Surveys (MeSH) |
9 | Computer Simulation (MeSH) |
9 | Animals, Wild (virology) |
8 | Zoonoses (transmission) |
8 | Practice Patterns, Physicians' (MeSH) |
8 | Pneumococcal Infections (prevention & control) |
8 | Mortality (trends) |
8 | Models, Economic (MeSH) |
8 | Influenza, Human (etiology) |
8 | Influenza A Virus, H7N7 Subtype (genetics) |
8 | Hospitalization (MeSH) |
8 | Global Health (MeSH) |
8 | Epidemics (MeSH) |
8 | Diagnosis, Differential (MeSH) |
7 | Virus Diseases (epidemiology) |
7 | Vaccination (methods) |
7 | Vaccination (adverse effects) |
7 | Turkeys (MeSH) |
7 | Respiratory Tract Diseases (epidemiology) |
7 | Respiratory Syncytial Virus Infections (epidemiology) |
7 | Reproducibility of Results (MeSH) |
7 | Qualitative Research (MeSH) |
7 | Poultry Diseases (transmission) |
7 | Poultry (virology) |
7 | Patient Acceptance of Health Care (MeSH) |
7 | Oseltamivir (MeSH) |
7 | Orthomyxoviridae (immunology) |
7 | Orthomyxoviridae (classification) |
7 | Multivariate Analysis (MeSH) |
7 | Molecular Sequence Data (MeSH) |
7 | Italy (epidemiology) |
7 | Influenza A virus (physiology) |
7 | Influenza A Virus, H5N8 Subtype (pathogenicity) |
7 | Influenza A Virus, H5N8 Subtype (genetics) |
7 | Influenza A Virus, H5N1 Subtype (genetics) |
7 | Influenza A Virus, H3N2 Subtype (MeSH) |
7 | Immunization Programs (statistics & numerical data) |
7 | History, 21st Century (MeSH) |
7 | Health Policy (MeSH) |
7 | Europe (epidemiology) |
7 | Enzyme-Linked Immunosorbent Assay (veterinary) |
7 | Communicable Diseases (epidemiology) |
7 | Communicable Disease Control (methods) |
7 | Cardiovascular Diseases (mortality) |
7 | Antiviral Agents (pharmacology) |
7 | Acetamides (therapeutic use) |
6 | Zoonoses (virology) |
6 | Virus Shedding (MeSH) |
6 | Virulence (MeSH) |
6 | Temperature (MeSH) |
6 | Swine Diseases (virology) |
6 | Societies, Medical (MeSH) |
6 | Reassortant Viruses (genetics) |
6 | Real-Time Polymerase Chain Reaction (MeSH) |
6 | Primary Health Care (MeSH) |
6 | Poultry Diseases (pathology) |
6 | Poisson Distribution (MeSH) |
6 | Pneumococcal Vaccines (administration & dosage) |
6 | Influenza, Human (history) |
6 | Influenza, Human (MeSH) |
6 | Ferrets (MeSH) |
6 | Fatal Outcome (MeSH) |
6 | Ducks (MeSH) |
6 | Disease Transmission, Infectious (prevention & control) |
6 | Cluster Analysis (MeSH) |
6 | Belgium (epidemiology) |
6 | Antibodies (MeSH) |
6 | Animals, Wild (MeSH) |
6 | Absenteeism (MeSH) |
5 | Virus Diseases (virology) |
5 | Virus Diseases (diagnosis) |
5 | Viral Proteins (genetics) |
5 | Vaccination (veterinary) |
5 | Swine Diseases (epidemiology) |
5 | Socioeconomic Factors (MeSH) |
5 | Sex Factors (MeSH) |
5 | Serotyping (MeSH) |
5 | Sentinel Surveillance (veterinary) |
5 | Security Measures (MeSH) |
5 | Schizophrenia (epidemiology) |
5 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
5 | Respiratory Tract Infections (microbiology) |
5 | Quality-Adjusted Life Years (MeSH) |
5 | Program Evaluation (MeSH) |
5 | Prognosis (MeSH) |
5 | Primary Prevention (MeSH) |
5 | Prenatal Exposure Delayed Effects (MeSH) |
5 | Predictive Value of Tests (MeSH) |
5 | Population Dynamics (MeSH) |
5 | Pneumococcal Infections (epidemiology) |
5 | Patient Acceptance of Health Care (statistics & numerical data) |
5 | Pandemics (statistics & numerical data) |
5 | Neuraminidase (genetics) |
5 | National Health Programs (MeSH) |
5 | Mutation (MeSH) |
5 | Mass Vaccination (MeSH) |
5 | Interviews as Topic (MeSH) |
5 | Influenza, Human (therapy) |
5 | Influenza, Human (pathology) |
5 | Influenza A Virus, H5N8 Subtype (isolation & purification) |
5 | Influenza A Virus, H5N1 Subtype (isolation & purification) |
5 | Influenza A Virus, H3N2 Subtype (isolation & purification) |
5 | History, 20th Century (MeSH) |
5 | Health Care Surveys (MeSH) |
5 | Health Behavior (MeSH) |
5 | Genetic Variation (MeSH) |
5 | General Practitioners (statistics & numerical data) |
5 | Forecasting (MeSH) |
5 | Follow-Up Studies (MeSH) |
5 | Family Practice (statistics & numerical data) |
5 | Europe (MeSH) |
5 | England (epidemiology) |
5 | Double-Blind Method (MeSH) |
5 | Disease Outbreaks (economics) |
5 | Demography (MeSH) |
5 | Decision Making (MeSH) |
5 | Databases, Factual (MeSH) |
5 | Confidence Intervals (MeSH) |
5 | Belgium (MeSH) |
5 | Attitude to Health (MeSH) |
5 | Asia (epidemiology) |
5 | Antiviral Agents (economics) |
5 | Antibodies, Viral (immunology) |
5 | Analysis of Variance (MeSH) |
5 | Air Pollution (adverse effects) |
5 | Adverse Drug Reaction Reporting Systems (MeSH) |
5 | Acute Disease (MeSH) |
4 | Zoonoses (epidemiology) |
4 | World Health Organization (MeSH) |
4 | Workforce (MeSH) |
4 | Wind (MeSH) |
4 | Wales (epidemiology) |
4 | Turkeys (virology) |
4 | Travel (MeSH) |
4 | Switzerland (epidemiology) |
4 | Schizophrenia (etiology) |
4 | Risk Assessment (methods) |
4 | Reverse Transcriptase Polymerase Chain Reaction (veterinary) |
4 | Respiratory Tract Diseases (mortality) |
4 | Reassortant Viruses (isolation & purification) |
4 | Quality Control (MeSH) |
4 | Publishing (MeSH) |
4 | Public Opinion (MeSH) |
4 | Polymerase Chain Reaction (methods) |
4 | Pneumonia (epidemiology) |
4 | Pneumococcal Vaccines (therapeutic use) |
4 | Pilot Projects (MeSH) |
4 | Patient Education as Topic (MeSH) |
4 | Patient Compliance (MeSH) |
4 | Outcome Assessment, Health Care (MeSH) |
4 | Occupational Exposure (MeSH) |
4 | Neuraminidase (antagonists & inhibitors) |
4 | Morbidity (MeSH) |
4 | Linear Models (MeSH) |
4 | Likelihood Functions (MeSH) |
4 | Intention (MeSH) |
4 | Influenza in Birds (immunology) |
4 | Influenza A virus (drug effects) |
4 | Influenza A Virus, H7N7 Subtype (isolation & purification) |
4 | Influenza A Virus, H5N8 Subtype (classification) |
4 | Influenza A Virus, H3N2 Subtype (immunology) |
4 | Influenza A Virus, H1N1 Subtype (physiology) |
4 | Influenza A Virus, H1N1 Subtype (drug effects) |
4 | Immunization Programs (economics) |
4 | Hospitals (MeSH) |
4 | Horses (MeSH) |
4 | Homes for the Aged (MeSH) |
4 | History, 19th Century (MeSH) |
4 | Health Personnel (statistics & numerical data) |
4 | Guidelines as Topic (MeSH) |
4 | Germany (MeSH) |
4 | General Practitioners (psychology) |
4 | Gastroenteritis (epidemiology) |
4 | Focus Groups (MeSH) |
4 | European Union (MeSH) |
4 | Epidemics (veterinary) |
4 | Epidemics (statistics & numerical data) |
4 | Enzyme-Linked Immunosorbent Assay (methods) |
4 | Environmental Exposure (adverse effects) |
4 | Ducks (virology) |
4 | Drug-Related Side Effects and Adverse Reactions (epidemiology) |
4 | Drug Resistance, Viral (MeSH) |
4 | Disease Outbreaks (history) |
4 | Disaster Planning (MeSH) |
4 | Data Collection (MeSH) |
4 | Cross Infection (prevention & control) |
4 | Cross Infection (epidemiology) |
4 | Comorbidity (MeSH) |
4 | Community-Acquired Infections (microbiology) |
4 | Communicable Diseases, Emerging (epidemiology) |
4 | Communicable Disease Control (MeSH) |
4 | Chronic Disease (MeSH) |
4 | China (epidemiology) |
4 | Chick Embryo (MeSH) |
4 | Cell Line (MeSH) |
4 | Bird Diseases (epidemiology) |
4 | Bayes Theorem (MeSH) |
4 | Antiviral Agents (administration & dosage) |
4 | Antigens, Viral (analysis) |
4 | Anti-Bacterial Agents (therapeutic use) |
4 | Air Pollutants (analysis) |
4 | Academic Medical Centers (MeSH) |
3 | Workload (MeSH) |
3 | Weather (MeSH) |
3 | Viruses (isolation & purification) |
3 | Viral Proteins (metabolism) |
3 | Viral Load (MeSH) |
3 | Veterinarians (MeSH) |
3 | Vaccination (trends) |
3 | Vaccination (standards) |
3 | Syndrome (MeSH) |
3 | Swine Diseases (transmission) |
3 | Sweden (epidemiology) |
3 | Sweden (MeSH) |
3 | Sulfur Dioxide (analysis) |
3 | Sulfur Dioxide (adverse effects) |
3 | Streptococcus pneumoniae (isolation & purification) |
3 | Stochastic Processes (MeSH) |
3 | Statistics as Topic (MeSH) |
3 | Species Specificity (MeSH) |
3 | Severe Acute Respiratory Syndrome (prevention & control) |
3 | Serologic Tests (MeSH) |
3 | Self Report (MeSH) |
3 | Schools (MeSH) |
3 | Salmonella Infections (epidemiology) |
3 | Respiratory Syncytial Virus Infections (virology) |
3 | Residence Characteristics (MeSH) |
3 | Research Design (MeSH) |
3 | Registries (statistics & numerical data) |
3 | Recurrence (MeSH) |
3 | Reassortant Viruses (pathogenicity) |
3 | RNA Replicase (genetics) |
3 | Primary Health Care (statistics & numerical data) |
3 | Pregnancy Trimester, Second (MeSH) |
3 | Pregnancy Outcome (MeSH) |
3 | Pregnancy Complications, Infectious (virology) |
3 | Pregnancy Complications, Infectious (prevention & control) |
3 | Practice Patterns, Physicians' (statistics & numerical data) |
3 | Poultry Diseases (diagnosis) |
3 | Population (MeSH) |
3 | Polymerase Chain Reaction (MeSH) |
3 | Pneumonia, Viral (epidemiology) |
3 | Pneumonia (mortality) |
3 | Pharmacovigilance (MeSH) |
3 | Parents (MeSH) |
3 | Paramyxoviridae Infections (epidemiology) |
3 | Oseltamivir (economics) |
3 | Oseltamivir (administration & dosage) |
3 | Orthomyxoviridae (pathogenicity) |
3 | Orthomyxoviridae (genetics) |
3 | Occupational Diseases (prevention & control) |
3 | Occupational Diseases (epidemiology) |
3 | Norway (epidemiology) |
3 | Needs Assessment (MeSH) |
3 | National Health Programs (organization & administration) |
3 | Nasopharynx (virology) |
3 | Motivation (MeSH) |
3 | Monte Carlo Method (MeSH) |
3 | Meat (virology) |
3 | Mass Media (MeSH) |
3 | Markov Chains (MeSH) |
3 | Lung Diseases (complications) |
3 | Lung (virology) |
3 | Length of Stay (MeSH) |
3 | Laboratories (MeSH) |
3 | Japan (MeSH) |
3 | International Cooperation (MeSH) |
3 | Intensive Care Units, Pediatric (MeSH) |
3 | Information Dissemination (MeSH) |
3 | Influenza, Human (veterinary) |
3 | Influenza, Human (ethnology) |
3 | Influenza in Birds (psychology) |
3 | Influenza Vaccines (supply & distribution) |
3 | Influenza B virus (pathogenicity) |
3 | Influenza B virus (genetics) |
3 | Influenza B virus (drug effects) |
3 | Influenza A Virus, H5N1 Subtype (immunology) |
3 | Influenza A Virus, H3N2 Subtype (genetics) |
3 | Immunization, Secondary (methods) |
3 | Immunization Schedule (MeSH) |
3 | Immunization Programs (organization & administration) |
3 | Immunization Programs (methods) |
3 | Hygiene (MeSH) |
3 | Hospitalization (economics) |
3 | Herpes Zoster (epidemiology) |
3 | Hepatitis B (prevention & control) |
3 | Hemagglutinin Glycoproteins, Influenza Virus (metabolism) |
3 | Hemagglutinin Glycoproteins, Influenza Virus (genetics) |
3 | Hemagglutinin Glycoproteins, Influenza Virus (chemistry) |
3 | Hemagglutination Inhibition Tests (veterinary) |
3 | Hemagglutination Inhibition Tests (methods) |
3 | Health Personnel (psychology) |
3 | Health Care Costs (MeSH) |
3 | Guideline Adherence (statistics & numerical data) |
3 | France (epidemiology) |
3 | Feasibility Studies (MeSH) |
3 | Family Practice (standards) |
3 | Family Characteristics (MeSH) |
3 | Epidemiological Monitoring (MeSH) |
3 | Epidemiologic Studies (MeSH) |
3 | Epidemiologic Methods (MeSH) |
3 | Enzyme Inhibitors (therapeutic use) |
3 | Drug Prescriptions (statistics & numerical data) |
3 | Disease Transmission, Infectious (statistics & numerical data) |
3 | Disease Susceptibility (epidemiology) |
3 | Disease (MeSH) |
3 | Developed Countries (MeSH) |
3 | Denmark (epidemiology) |
3 | Cough (epidemiology) |
3 | Conjunctivitis, Viral (virology) |
3 | Conjunctivitis, Viral (epidemiology) |
3 | Confounding Factors, Epidemiologic (MeSH) |
3 | Complement Fixation Tests (MeSH) |
3 | Clinical Trials as Topic (MeSH) |
3 | Classical Swine Fever (epidemiology) |
3 | Choice Behavior (MeSH) |
3 | Charadriiformes (MeSH) |
3 | Cause of Death (trends) |
3 | Biomedical Research (methods) |
3 | Bacterial Infections (epidemiology) |
3 | Asthma (complications) |
3 | Antigens, Viral (immunology) |
3 | Antibodies, Viral (isolation & purification) |
3 | Antibodies, Viral (analysis) |
3 | Amino Acid Substitution (MeSH) |
3 | Air Pollution (analysis) |
3 | Air Pollutants (adverse effects) |
3 | Aging (MeSH) |
3 | Advisory Committees (MeSH) |
3 | Adjuvants, Immunologic (MeSH) |
2 | Zanamivir (therapeutic use) |
2 | Zanamivir (MeSH) |
2 | Whooping Cough (epidemiology) |
2 | Whole Genome Sequencing (MeSH) |
2 | Virus Replication (MeSH) |
2 | Virus Diseases (veterinary) |
2 | Virus Diseases (complications) |
2 | Virus Diseases (MeSH) |
2 | Veterinarians (psychology) |
2 | Vehicle Emissions (adverse effects) |
2 | Vaccines, Conjugate (MeSH) |
2 | Vaccines (adverse effects) |
2 | United States (epidemiology) |
2 | United Kingdom (MeSH) |
2 | Trust (MeSH) |
2 | Treatment Refusal (MeSH) |
2 | Tetanus Toxoid (therapeutic use) |
2 | Tetanus Toxoid (MeSH) |
2 | Tetanus (prevention & control) |
2 | Tertiary Care Centers (MeSH) |
2 | T-Lymphocytes (immunology) |
2 | Swine Diseases (prevention & control) |
2 | Swine Diseases (immunology) |
2 | Swine (virology) |
2 | Swine (microbiology) |
2 | Survival Rate (MeSH) |
2 | Survival Analysis (MeSH) |